 BOSTON, Sept. 14, 2021 PRNewswire -- Stealth BioTherapeutics Corp Nasdaq: MITO, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today that multiple abstracts have been accepted for presentation at several leading ophthalmic conferences this fall. 